Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice

Item Type:	Article
Title:	Anti-tumor activity of Titanocene Y in xenografted Caki-1 tumors in mice
Creators Name:	Fichtner, I. and Pampillon, C. and Sweeney, N.J. and Strohfeldt, K. and Tacke, M.
Abstract:	The benzyl-substituted unbridged titanocene bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) was tested in vitro against human renal cancer cells (Caki-1), in which it showed an IC50 value of 36 x 10 mol/l. Titanocene Y was then given in vivo in doses of 10, 20, 30, 40 and 50 mg/kg on 5 consecutive days to Caki-1-bearing mice, and it showed concentration-dependent and statistically significant tumor growth reduction with respect to a solvent-treated control cohort. The maximum tolerable dose of Titanocene Y was determined to be 40 mg/kg and it showed significantly better tumor volume growth reduction than cisplatin given at a dose of 2 mg/kg. This superior activity of Titanocene Y with respect to cisplatin will hopefully lead to clinical tests against metastatic renal cell cancer in the near future.
Keywords:	Anti-Cancer Drug, Caki-1, Cisplatin, Renal Cell Cancer, Titanocene, Animals, Mice
Source:	Anti-Cancer Drugs
ISSN:	0959-4973
Publisher:	Lippincott Williams & Wilkins
Volume:	17
Number:	3
Page Range:	333-336
Date:	March 2006
PubMed:	View item in PubMed

Repository Staff Only: item control page